Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
Metrics: PDF 2120 views | HTML 3001 views | ?
1Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany
Keywords: cancer, apoptosis, chemotherapy, proteasome inhibitor, TRAIL
Received: April 19, 2011; Accepted: May 14, 2011; Published: May 16, 2011;
Simone Fulda, e-mail:
The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.